Pharmacology and Antitumor Activity of ABC294640, a Selective Inhibitor of Sphingosine Kinase-2
Kevin J. French(GlaxoSmithKline (United States)), Charles D. Smith(Apogee Biotechnology (United States))
Cited by 313
Related Papers
A Novel Sphingosine Kinase Inhibitor Induces Autophagy in Tumor Cells
|Journal of Pharmacology and Experimental Therapeutics|2010|111
Recent Progress in the Development of Opaganib for the Treatment of Covid-19
|Drug Design Development and Therapy|2022|27
Opaganib (ABC294640) Induces Immunogenic Tumor Cell Death and Enhances Checkpoint Antibody Therapy
|International Journal of Molecular Sciences|2023|18
In Vitro and In Vivo Antitumor and Anti-Inflammatory Capabilities of the Novel GSK3 and CDK9 Inhibitor ABC1183
|Journal of Pharmacology and Experimental Therapeutics|2018|16